Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in February 2016 on request of the Sponsor.
On 6 December 2012, orphan designation (EU/3/12/1082) was granted by the European Commission to B. Braun Melsungen AG, Germany, for triheptanoin for the treatment of long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
|Disease / condition||
Treatment of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
Tel. +49 56 61 710
Fax +49 56 61 71 2950
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.